[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frS1d-9SSp6qFjrTDG7BhvXf8ijGaGHBcGF-wfF8SKE0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":83,"rows":90},"BioMarin Pharmaceutical",[4],112,false,28,27,11998,21,20,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Phenylketonuria",18,{"name":18,"count":19},"Achondroplasia",14,{"name":21,"count":22},"Duchenne Muscular Dystrophy",8,{"name":24,"count":22},"Morquio A Syndrome",{"name":26,"count":22},"Hemophilia A",{"name":28,"count":29},"Phenylketonuria (PKU)",7,{"name":31,"count":32},"MPS IVA",6,{"name":34,"count":32},"Mucopolysaccharidosis IVA",[36,41,46,51,56,60,65,70,74,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05270837","Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria","2025-01-14","Pegvaliase",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06224907","Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A","2025-04-16","Valoctocogene roxaparvovec",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06382155","A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature","2026-06","Vosoritide",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06780332","Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq","2026-08","RDD to Palynziq",{"nctId":57,"briefTitle":58,"date":59,"intervention":50},"NCT06455059","Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia","2026-08-01",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06738017","Study of BMN 349 Single Dose in PiZZ and PiMZ\u002FMASH Adult Participants","2026-08-19","BMN 349",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06280209","A Phase 1\u002F2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy","2026-09-30","BMN 351",{"nctId":71,"briefTitle":72,"date":73,"intervention":50},"NCT06668805","A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment","2027-03",{"nctId":75,"briefTitle":76,"date":77,"intervention":40},"NCT07477691","Immune Modulation During Palynziq® Treatment in Adults (IMPALA)","2027-09-30",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04480567","AAV Gene Therapy Study for Subjects with PKU","2027-12","BMN 307",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,163,181,202,269,353,422,448,466,493,512,536,554,586,604,622,640,658,676,694,714,738,772,797,845,887,920,946,964,990,1008,1033,1059,1077,1119,1153,1181,1199,1217,1235,1253,1278,1296,1314,1341,1359,1377,1395,1413,1436,1459,1477,1502,1527,1554,1577,1605,1623,1641,1659,1677,1695,1720,1738,1756,1781,1799,1817,1842,1860,1887,1985,2052,2092,2129,2154],{"intervention":40,"totalTrials":32,"cells":92},{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":121,"NA":131},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":120,"soonestReadout":39},[102,110],{"nctId":37,"briefTitle":38,"status":103,"phases":104,"primaryCompletion":39,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"ACTIVE_NOT_RECRUITING",[87],"2027-10","2022-06-17",55,[28],[40],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT03694353","Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg\u002FDay Dose) in Adults With PKU","COMPLETED",[87],"2021-01-13","2018-09-13",37,[28],[40],1,{"trials":122,"activeCount":120,"soonestReadout":77},[123],{"nctId":75,"briefTitle":76,"status":124,"phases":125,"primaryCompletion":77,"completion":77,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NOT_YET_RECRUITING",[88],"2026-03-31",12,[15],[40,130],"Methotrexate",{"trials":132,"activeCount":162,"soonestReadout":138},[133,144,153],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT05579548","A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding","RECRUITING",[],"2032-10-04","2022-11-22",50,[142],"Phenylketonuria, Maternal",[40],{"nctId":145,"briefTitle":146,"status":136,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"NCT06305234","A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)",[],"2033-11-18","2024-01-20",200,[28],[40],{"nctId":154,"briefTitle":155,"status":136,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT05813678","A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)",[],"2033-11-01","2022-06-06",450,[28],[40],3,{"intervention":130,"totalTrials":120,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":179},{"trials":166,"activeCount":95},[],{"trials":168,"activeCount":95},[],{"trials":170,"activeCount":95},[],{"trials":172,"activeCount":95},[],{"trials":174,"activeCount":120,"soonestReadout":77},[175],{"nctId":75,"briefTitle":76,"status":124,"phases":176,"primaryCompletion":77,"completion":77,"start":126,"enrollment":127,"conditions":177,"interventions":178},[88],[15],[40,130],{"trials":180,"activeCount":95},[],{"intervention":55,"totalTrials":120,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":200},{"trials":184,"activeCount":95},[],{"trials":186,"activeCount":95},[],{"trials":188,"activeCount":95},[],{"trials":190,"activeCount":95},[],{"trials":192,"activeCount":120,"soonestReadout":54},[193],{"nctId":52,"briefTitle":53,"status":103,"phases":194,"primaryCompletion":54,"completion":54,"start":195,"enrollment":196,"conditions":197,"interventions":199},[88],"2025-02-07",9,[15,198],"PKU",[55],{"trials":201,"activeCount":95},[],{"intervention":50,"totalTrials":32,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":246,"PHASE4":265,"NA":267},{"trials":205,"activeCount":95},[],{"trials":207,"activeCount":95},[],{"trials":209,"activeCount":245,"soonestReadout":49},[210,218,228,237],{"nctId":71,"briefTitle":72,"status":136,"phases":211,"primaryCompletion":73,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},[86],"2041-09","2024-11-22",30,[216],"Noonan Syndrome",[50],{"nctId":219,"briefTitle":220,"status":136,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT07126262","A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to \u003C 36 Months",[86],"2028-06-30","2025-07-30",60,[226],"Hypochondroplasia",[50],{"nctId":47,"briefTitle":48,"status":136,"phases":229,"primaryCompletion":49,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},[86],"2036-12","2024-10-21",100,[234],"Idiopathic Short Stature",[50,236],"Human Growth Hormone",{"nctId":238,"briefTitle":239,"status":103,"phases":240,"primaryCompletion":81,"completion":81,"start":241,"enrollment":12,"conditions":242,"interventions":243},"NCT04554940","A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia",[86],"2020-10-10",[18],[244],"vosoritide",4,{"trials":247,"activeCount":264,"soonestReadout":59},[248,254],{"nctId":57,"briefTitle":58,"status":103,"phases":249,"primaryCompletion":59,"completion":59,"start":250,"enrollment":251,"conditions":252,"interventions":253},[87],"2024-06-17",80,[226],[50],{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT07073014","Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia","ENROLLING_BY_INVITATION",[87],"2040-12","2025-06-20",140,[226],[50],2,{"trials":266,"activeCount":95},[],{"trials":268,"activeCount":95},[],{"intervention":270,"totalTrials":29,"cells":271},"valoctocogene roxaparvovec",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":312,"PHASE4":349,"NA":351},{"trials":273,"activeCount":95},[],{"trials":275,"activeCount":95},[],{"trials":277,"activeCount":120,"soonestReadout":282},[278,289,302],{"nctId":279,"briefTitle":280,"status":103,"phases":281,"primaryCompletion":282,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":288},"NCT04684940","Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors",[85,86],"2029-04","2020-12-10",10,[286,287],"Hemophilia A With Inhibitor","Hemophilia A With Anti Factor VIII",[45],{"nctId":290,"briefTitle":291,"status":292,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":162,"conditions":296,"interventions":300},"NCT03520712","Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5","TERMINATED",[85,86],"2024-08-07","2018-04-24",[26,297,298,299],"Gene Therapy","Clotting Disorders","Blood Disorder",[301],"Valoctocogene Roxaparvovec",{"nctId":303,"briefTitle":304,"status":113,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT02576795","Gene Therapy Study in Severe Haemophilia A Patients (270-201)",[85,86],"2024-02-14","2015-09-28",15,[310],"Severe Haemophilia A",[270],{"trials":313,"activeCount":120,"soonestReadout":44},[314,324,333,343],{"nctId":315,"briefTitle":316,"status":113,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT03370913","Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)",[87],"2020-11-16","2024-11-20","2017-12-19",144,[26],[270],{"nctId":325,"briefTitle":326,"status":113,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":120,"conditions":331,"interventions":332},"NCT03392974","Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg\u002Fkg",[87],"2019-05-22","2023-06-05","2018-03-14",[26],[301],{"nctId":334,"briefTitle":335,"status":113,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":342},"NCT04323098","Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A",[87],"2023-01-27","2025-05-08","2020-12-08",22,[26],[270],{"nctId":42,"briefTitle":43,"status":103,"phases":344,"primaryCompletion":44,"completion":345,"start":346,"enrollment":32,"conditions":347,"interventions":348},[87],"2029-03","2023-12-25",[26],[45],{"trials":350,"activeCount":95},[],{"trials":352,"activeCount":95},[],{"intervention":354,"totalTrials":32,"cells":355},"BMN 111",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":370,"PHASE3":398,"PHASE4":418,"NA":420},{"trials":357,"activeCount":95},[],{"trials":359,"activeCount":95},[360],{"nctId":361,"briefTitle":362,"status":113,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":368},"NCT01590446","A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers",[85],"2012-06","2012-02",74,[18],[354,369],"Normal Saline",{"trials":371,"activeCount":120,"soonestReadout":81},[372,381,389],{"nctId":373,"briefTitle":374,"status":113,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT02055157","A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia",[86],"2017-10-02","2014-01-13",35,[18],[354],{"nctId":382,"briefTitle":383,"status":103,"phases":384,"primaryCompletion":81,"completion":385,"start":386,"enrollment":214,"conditions":387,"interventions":388},"NCT02724228","A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)",[86],"2028-02","2016-01-26",[18],[354],{"nctId":390,"briefTitle":391,"status":113,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT03583697","A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia",[86],"2022-01-26","2018-06-13",75,[18],[354],{"trials":399,"activeCount":120,"soonestReadout":413},[400,409],{"nctId":401,"briefTitle":402,"status":113,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT03197766","A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia",[87],"2019-10-30","2016-12-12",121,[18],[354],{"nctId":410,"briefTitle":411,"status":103,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT03424018","An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia",[87],"2031-06","2017-12-12",119,[18],[354],{"trials":419,"activeCount":95},[],{"trials":421,"activeCount":95},[],{"intervention":423,"totalTrials":120,"cells":424},"BMN 333",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":444,"NA":446},{"trials":426,"activeCount":95},[],{"trials":428,"activeCount":95},[],{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":120,"soonestReadout":437},[433],{"nctId":434,"briefTitle":435,"status":136,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT07441876","Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia",[86,87],"2029-06","2029-09","2026-04",160,[18],[423,443],"Vosoritide Injection [Voxzogo]",{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"intervention":443,"totalTrials":120,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":462,"NA":464},{"trials":451,"activeCount":95},[],{"trials":453,"activeCount":95},[],{"trials":455,"activeCount":95},[],{"trials":457,"activeCount":120,"soonestReadout":437},[458],{"nctId":434,"briefTitle":435,"status":136,"phases":459,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":460,"interventions":461},[86,87],[18],[423,443],{"trials":463,"activeCount":95},[],{"trials":465,"activeCount":95},[],{"intervention":69,"totalTrials":264,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":469,"activeCount":95},[],{"trials":471,"activeCount":95},[],{"trials":473,"activeCount":264,"soonestReadout":68},[474,479],{"nctId":66,"briefTitle":67,"status":136,"phases":475,"primaryCompletion":68,"completion":68,"start":476,"enrollment":16,"conditions":477,"interventions":478},[85,86],"2024-01-03",[21],[69],{"nctId":480,"briefTitle":481,"status":257,"phases":482,"primaryCompletion":483,"completion":483,"start":439,"enrollment":16,"conditions":484,"interventions":486},"NCT07573631","An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy",[86],"2031-12",[485],"Duchenne Muscular Dystrophy (DMD)",[69],{"trials":488,"activeCount":95},[],{"trials":490,"activeCount":95},[],{"trials":492,"activeCount":95},[],{"intervention":82,"totalTrials":120,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":496,"activeCount":95},[],{"trials":498,"activeCount":95},[],{"trials":500,"activeCount":120,"soonestReadout":81},[501],{"nctId":79,"briefTitle":80,"status":103,"phases":502,"primaryCompletion":81,"completion":81,"start":503,"enrollment":232,"conditions":504,"interventions":505},[85,86],"2020-09-24",[28],[82],{"trials":507,"activeCount":95},[],{"trials":509,"activeCount":95},[],{"trials":511,"activeCount":95},[],{"intervention":513,"totalTrials":120,"cells":514},"Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":516,"activeCount":95},[],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":120,"soonestReadout":525},[521],{"nctId":522,"briefTitle":523,"status":103,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":529},"NCT03989947","An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia",[86],"2038-05","2019-06-12",73,[18],[513],{"trials":531,"activeCount":95},[],{"trials":533,"activeCount":95},[],{"trials":535,"activeCount":95},[],{"intervention":236,"totalTrials":120,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":539,"activeCount":95},[],{"trials":541,"activeCount":95},[],{"trials":543,"activeCount":120,"soonestReadout":49},[544],{"nctId":47,"briefTitle":48,"status":136,"phases":545,"primaryCompletion":49,"completion":230,"start":231,"enrollment":232,"conditions":546,"interventions":547},[86],[234],[50,236],{"trials":549,"activeCount":95},[],{"trials":551,"activeCount":95},[],{"trials":553,"activeCount":95},[],{"intervention":555,"totalTrials":120,"cells":556},"Dose 1 of BMN 331",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":95},[],{"trials":562,"activeCount":120,"soonestReadout":567},[563],{"nctId":564,"briefTitle":565,"status":103,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":573},"NCT05121376","A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema",[85,86],"2028-11","2022-02-15",44,[571,572],"Hereditary Angioedema","HAE",[555,574,575,576,577,578,579],"Dose 2 of BMN 331","Dose 3 of BMN 331","Dose 4 of BMN 331","Dose 5 of BMN 331","Dose 6 of BMN 331","Dose 7 of BMN 331",{"trials":581,"activeCount":95},[],{"trials":583,"activeCount":95},[],{"trials":585,"activeCount":95},[],{"intervention":574,"totalTrials":120,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":589,"activeCount":95},[],{"trials":591,"activeCount":95},[],{"trials":593,"activeCount":120,"soonestReadout":567},[594],{"nctId":564,"briefTitle":565,"status":103,"phases":595,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":596,"interventions":597},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":599,"activeCount":95},[],{"trials":601,"activeCount":95},[],{"trials":603,"activeCount":95},[],{"intervention":575,"totalTrials":120,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":607,"activeCount":95},[],{"trials":609,"activeCount":95},[],{"trials":611,"activeCount":120,"soonestReadout":567},[612],{"nctId":564,"briefTitle":565,"status":103,"phases":613,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":614,"interventions":615},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":617,"activeCount":95},[],{"trials":619,"activeCount":95},[],{"trials":621,"activeCount":95},[],{"intervention":576,"totalTrials":120,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":625,"activeCount":95},[],{"trials":627,"activeCount":95},[],{"trials":629,"activeCount":120,"soonestReadout":567},[630],{"nctId":564,"briefTitle":565,"status":103,"phases":631,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":632,"interventions":633},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":635,"activeCount":95},[],{"trials":637,"activeCount":95},[],{"trials":639,"activeCount":95},[],{"intervention":577,"totalTrials":120,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":643,"activeCount":95},[],{"trials":645,"activeCount":95},[],{"trials":647,"activeCount":120,"soonestReadout":567},[648],{"nctId":564,"briefTitle":565,"status":103,"phases":649,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":650,"interventions":651},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":653,"activeCount":95},[],{"trials":655,"activeCount":95},[],{"trials":657,"activeCount":95},[],{"intervention":578,"totalTrials":120,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":661,"activeCount":95},[],{"trials":663,"activeCount":95},[],{"trials":665,"activeCount":120,"soonestReadout":567},[666],{"nctId":564,"briefTitle":565,"status":103,"phases":667,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":668,"interventions":669},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":671,"activeCount":95},[],{"trials":673,"activeCount":95},[],{"trials":675,"activeCount":95},[],{"intervention":579,"totalTrials":120,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":679,"activeCount":95},[],{"trials":681,"activeCount":95},[],{"trials":683,"activeCount":120,"soonestReadout":567},[684],{"nctId":564,"briefTitle":565,"status":103,"phases":685,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":686,"interventions":687},[85,86],[571,572],[555,574,575,576,577,578,579],{"trials":689,"activeCount":95},[],{"trials":691,"activeCount":95},[],{"trials":693,"activeCount":95},[],{"intervention":64,"totalTrials":120,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":697,"activeCount":95},[],{"trials":699,"activeCount":120,"soonestReadout":63},[700],{"nctId":61,"briefTitle":62,"status":103,"phases":701,"primaryCompletion":63,"completion":63,"start":702,"enrollment":32,"conditions":703,"interventions":705},[85],"2025-02-21",[704],"Alpha 1-Antitrypsin Deficiency",[64],{"trials":707,"activeCount":95},[],{"trials":709,"activeCount":95},[],{"trials":711,"activeCount":95},[],{"trials":713,"activeCount":95},[],{"intervention":715,"totalTrials":120,"cells":716},"Cerliponase Alfa",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":718,"activeCount":95},[],{"trials":720,"activeCount":95},[],{"trials":722,"activeCount":95},[],{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[],{"trials":728,"activeCount":120,"soonestReadout":733},[729],{"nctId":730,"briefTitle":731,"status":103,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":378,"conditions":735,"interventions":737},"NCT04476862","Cerliponase Alfa Observational Study in the US",[],"2030-08-31","2020-08-19",[736],"Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2",[715],{"intervention":739,"totalTrials":264,"cells":740},"Kuvan®",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":759,"NA":770},{"trials":742,"activeCount":95},[],{"trials":744,"activeCount":95},[],{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[749],{"nctId":750,"briefTitle":751,"status":113,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":758},"NCT01376908","Kuvan® in Phenylketonuria Patients Less Than 4 Years Old",[87],"2014-07","2017-02-17","2011-06",56,[15],[739],{"trials":760,"activeCount":95},[761],{"nctId":762,"briefTitle":763,"status":113,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT01965912","Kuvan®'s Effect on the Cognition of Children With Phenylketonuria",[88],"2023-01-04","2013-10",34,[15],[739],{"trials":771,"activeCount":95},[],{"intervention":773,"totalTrials":120,"cells":774},"Naglazyme",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":795},{"trials":776,"activeCount":95},[],{"trials":778,"activeCount":95},[],{"trials":780,"activeCount":95},[],{"trials":782,"activeCount":95},[],{"trials":784,"activeCount":95},[785],{"nctId":786,"briefTitle":787,"status":113,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":245,"conditions":791,"interventions":794},"NCT00299000","A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI",[88],"2009-04","2006-05",[792,793],"Mucopolysaccharidosis VI","Maroteaux-Lamy Syndrome",[773],{"trials":796,"activeCount":95},[],{"intervention":798,"totalTrials":245,"cells":799},"N-acetylgalactosamine 4-sulfatase",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":812,"PHASE3":822,"PHASE4":841,"NA":843},{"trials":801,"activeCount":95},[],{"trials":803,"activeCount":95},[804],{"nctId":805,"briefTitle":806,"status":113,"phases":807,"completion":808,"start":809,"conditions":810,"interventions":811},"NCT00048620","Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI",[85],"2005-11","2000-09",[792],[798],{"trials":813,"activeCount":95},[814],{"nctId":815,"briefTitle":816,"status":113,"phases":817,"completion":818,"start":819,"conditions":820,"interventions":821},"NCT00048711","Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI",[86],"2006-06","2002-03",[792],[798],{"trials":823,"activeCount":95},[824,833],{"nctId":825,"briefTitle":826,"status":113,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT00104234","Study of rhASB in Patients With Mucopolysaccharidosis VI",[87],"2006-10","2004-02",39,[792],[798],{"nctId":834,"briefTitle":835,"status":113,"phases":836,"completion":837,"start":838,"enrollment":830,"conditions":839,"interventions":840},"NCT00067470","Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI",[87],"2004-03","2003-09",[792],[798],{"trials":842,"activeCount":95},[],{"trials":844,"activeCount":95},[],{"intervention":846,"totalTrials":162,"cells":847},"BMN 701",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":871,"PHASE4":883,"NA":885},{"trials":849,"activeCount":95},[],{"trials":851,"activeCount":95},[],{"trials":853,"activeCount":95},[854,863],{"nctId":855,"briefTitle":856,"status":292,"phases":857,"primaryCompletion":858,"completion":858,"start":859,"enrollment":11,"conditions":860,"interventions":862},"NCT01435772","Extension Study for Patients Who Have Participated in a BMN 701 Study",[86],"2016-09-09","2011-08-15",[861],"Pompe Disease",[846],{"nctId":864,"briefTitle":865,"status":113,"phases":866,"primaryCompletion":867,"completion":867,"start":868,"enrollment":340,"conditions":869,"interventions":870},"NCT01230801","Safety\u002FTolerability\u002FPharmacokinetic (PK)\u002FPharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease",[85,86],"2013-03-06","2011-01-17",[861],[846],{"trials":872,"activeCount":95},[873],{"nctId":874,"briefTitle":875,"status":292,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":882},"NCT01924845","BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)",[87],"2016-09-12","2014-04",24,[881],"Late-onset Pompe Disease",[846],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"intervention":888,"totalTrials":264,"cells":889},"BMN 165",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":905,"PHASE4":916,"NA":918},{"trials":891,"activeCount":95},[],{"trials":893,"activeCount":95},[],{"trials":895,"activeCount":95},[896],{"nctId":897,"briefTitle":898,"status":113,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":879,"conditions":903,"interventions":904},"NCT01560286","A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks",[86],"2013-09","2015-07","2012-05",[15],[888],{"trials":906,"activeCount":95},[907],{"nctId":908,"briefTitle":909,"status":113,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":915},"NCT01819727","An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w\u002F BMN 165",[87],"2015-11-25","2013-05",261,[15],[888],{"trials":917,"activeCount":95},[],{"trials":919,"activeCount":95},[],{"intervention":921,"totalTrials":120,"cells":922},"BMN 110 Weekly",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":942,"NA":944},{"trials":924,"activeCount":95},[],{"trials":926,"activeCount":95},[],{"trials":928,"activeCount":95},[],{"trials":930,"activeCount":95},[931],{"nctId":932,"briefTitle":933,"status":113,"phases":934,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":940},"NCT01275066","A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",[87],"2012-08","2011-02",177,[939],"MPS IV A",[921,941],"BMN 110 Every Other Week",{"trials":943,"activeCount":95},[],{"trials":945,"activeCount":95},[],{"intervention":941,"totalTrials":120,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":960,"NA":962},{"trials":949,"activeCount":95},[],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"trials":955,"activeCount":95},[956],{"nctId":932,"briefTitle":933,"status":113,"phases":957,"primaryCompletion":935,"completion":935,"start":936,"enrollment":937,"conditions":958,"interventions":959},[87],[939],[921,941],{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[],{"intervention":965,"totalTrials":120,"cells":966},"BMN165 20mg\u002Fday",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":986,"NA":988},{"trials":968,"activeCount":95},[],{"trials":970,"activeCount":95},[],{"trials":972,"activeCount":95},[],{"trials":974,"activeCount":95},[975],{"nctId":976,"briefTitle":977,"status":113,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":984},"NCT01889862","Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU",[87],"2016-01-13","2019-02-05","2013-07-29",215,[28],[965,985],"BMN165 40mg\u002Fday",{"trials":987,"activeCount":95},[],{"trials":989,"activeCount":95},[],{"intervention":985,"totalTrials":120,"cells":991},{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":998,"PHASE4":1004,"NA":1006},{"trials":993,"activeCount":95},[],{"trials":995,"activeCount":95},[],{"trials":997,"activeCount":95},[],{"trials":999,"activeCount":95},[1000],{"nctId":976,"briefTitle":977,"status":113,"phases":1001,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":1002,"interventions":1003},[87],[28],[965,985],{"trials":1005,"activeCount":95},[],{"trials":1007,"activeCount":95},[],{"intervention":1009,"totalTrials":120,"cells":1010},"sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin",{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1029,"NA":1031},{"trials":1012,"activeCount":95},[],{"trials":1014,"activeCount":95},[],{"trials":1016,"activeCount":95},[],{"trials":1018,"activeCount":95},[1019],{"nctId":1020,"briefTitle":1021,"status":113,"phases":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT00104247","Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels",[87],"2006-02","2005-03",89,[1027],"Phenylketonurias",[1009],{"trials":1030,"activeCount":95},[],{"trials":1032,"activeCount":95},[],{"intervention":1034,"totalTrials":120,"cells":1035},"BMN 110 - Weekly",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1055,"NA":1057},{"trials":1037,"activeCount":95},[],{"trials":1039,"activeCount":95},[],{"trials":1041,"activeCount":95},[],{"trials":1043,"activeCount":95},[1044],{"nctId":1045,"briefTitle":1046,"status":113,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1053},"NCT01415427","Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",[87],"2016-06-16","2011-07",173,[1052,24,31],"Mucopolysaccharidosis IV A",[1034,1054],"BMN 110 - Every Other Week",{"trials":1056,"activeCount":95},[],{"trials":1058,"activeCount":95},[],{"intervention":1054,"totalTrials":120,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":95},[],{"trials":1064,"activeCount":95},[],{"trials":1066,"activeCount":95},[],{"trials":1068,"activeCount":95},[1069],{"nctId":1045,"briefTitle":1046,"status":113,"phases":1070,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":1050,"conditions":1071,"interventions":1072},[87],[1052,24,31],[1034,1054],{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"intervention":1078,"totalTrials":162,"cells":1079},"rAvPAL-PEG",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1093,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1081,"activeCount":95},[],{"trials":1083,"activeCount":95},[1084],{"nctId":1085,"briefTitle":1086,"status":113,"phases":1087,"primaryCompletion":789,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT00634660","Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria",[85],"2009-10","2008-05",25,[15],[1078],{"trials":1094,"activeCount":95},[1095,1104],{"nctId":1096,"briefTitle":1097,"status":113,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT01212744","Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)",[86],"2015-04","2011-03",16,[15],[1078],{"nctId":1105,"briefTitle":1106,"status":113,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT00924703","Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)",[86],"2019-01-31","2010-01-13",68,[15],[1078],{"trials":1114,"activeCount":95},[],{"trials":1116,"activeCount":95},[],{"trials":1118,"activeCount":95},[],{"intervention":1120,"totalTrials":264,"cells":1121},"BMN 190",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1123,"activeCount":95},[],{"trials":1125,"activeCount":95},[],{"trials":1127,"activeCount":95},[1128,1140],{"nctId":1129,"briefTitle":1130,"status":113,"phases":1131,"primaryCompletion":283,"completion":283,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1139},"NCT02485899","An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease",[85,86],"2015-02",23,[1135,1136,736,1137,1138],"Jansky-Bielschowsky Disease","Batten Disease","CLN2 Disease","CLN2 Disorder",[1120],{"nctId":1141,"briefTitle":1142,"status":113,"phases":1143,"primaryCompletion":1144,"completion":1144,"start":900,"enrollment":879,"conditions":1145,"interventions":1146},"NCT01907087","A Phase 1\u002F2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease",[85,86],"2015-11",[1135,1136,736,1137],[1120],{"trials":1148,"activeCount":95},[],{"trials":1150,"activeCount":95},[],{"trials":1152,"activeCount":95},[],{"intervention":1154,"totalTrials":120,"cells":1155},"rAvPAL-PEG 0.001 mg\u002Fkg",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1157,"activeCount":95},[],{"trials":1159,"activeCount":95},[],{"trials":1161,"activeCount":95},[1162],{"nctId":1163,"briefTitle":1164,"status":113,"phases":1165,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1170},"NCT00925054","Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU",[86],"2015-06","2009-09",40,[15],[1154,1171,1172,1173,1174],"rAvPAL-PEG 0.003 mg\u002Fkg","rAvPAL-PEG 0.01 mg\u002Fkg","rAvPAL-PEG 0.03 mg\u002Fkg","rAvPAL-PEG 0.1 mg\u002Fkg",{"trials":1176,"activeCount":95},[],{"trials":1178,"activeCount":95},[],{"trials":1180,"activeCount":95},[],{"intervention":1171,"totalTrials":120,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":95},[],{"trials":1186,"activeCount":95},[],{"trials":1188,"activeCount":95},[1189],{"nctId":1163,"briefTitle":1164,"status":113,"phases":1190,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1191,"interventions":1192},[86],[15],[1154,1171,1172,1173,1174],{"trials":1194,"activeCount":95},[],{"trials":1196,"activeCount":95},[],{"trials":1198,"activeCount":95},[],{"intervention":1172,"totalTrials":120,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":95},[],{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[1207],{"nctId":1163,"briefTitle":1164,"status":113,"phases":1208,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1209,"interventions":1210},[86],[15],[1154,1171,1172,1173,1174],{"trials":1212,"activeCount":95},[],{"trials":1214,"activeCount":95},[],{"trials":1216,"activeCount":95},[],{"intervention":1173,"totalTrials":120,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":95},[],{"trials":1222,"activeCount":95},[],{"trials":1224,"activeCount":95},[1225],{"nctId":1163,"briefTitle":1164,"status":113,"phases":1226,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1227,"interventions":1228},[86],[15],[1154,1171,1172,1173,1174],{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[],{"trials":1234,"activeCount":95},[],{"intervention":1174,"totalTrials":120,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":95},[],{"trials":1240,"activeCount":95},[],{"trials":1242,"activeCount":95},[1243],{"nctId":1163,"briefTitle":1164,"status":113,"phases":1244,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1245,"interventions":1246},[86],[15],[1154,1171,1172,1173,1174],{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[],{"trials":1252,"activeCount":95},[],{"intervention":1254,"totalTrials":120,"cells":1255},"BMN 044 IV 6 mg\u002Fkg",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":95},[],{"trials":1261,"activeCount":95},[1262],{"nctId":1263,"briefTitle":1264,"status":292,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":29,"conditions":1268,"interventions":1269},"NCT02958202","Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)",[86],"2016-09","2016-04",[21],[1254,1270,1271],"BMN 044 IV 9 mg\u002Fkg","BMN 044 SC 6 mg\u002Fkg",{"trials":1273,"activeCount":95},[],{"trials":1275,"activeCount":95},[],{"trials":1277,"activeCount":95},[],{"intervention":1270,"totalTrials":120,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":95},[],{"trials":1283,"activeCount":95},[],{"trials":1285,"activeCount":95},[1286],{"nctId":1263,"briefTitle":1264,"status":292,"phases":1287,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":29,"conditions":1288,"interventions":1289},[86],[21],[1254,1270,1271],{"trials":1291,"activeCount":95},[],{"trials":1293,"activeCount":95},[],{"trials":1295,"activeCount":95},[],{"intervention":1271,"totalTrials":120,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":95},[1304],{"nctId":1263,"briefTitle":1264,"status":292,"phases":1305,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":29,"conditions":1306,"interventions":1307},[86],[21],[1254,1270,1271],{"trials":1309,"activeCount":95},[],{"trials":1311,"activeCount":95},[],{"trials":1313,"activeCount":95},[],{"intervention":1315,"totalTrials":120,"cells":1316},"Regimen Selection Phase Group 2",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1318,"activeCount":95},[],{"trials":1320,"activeCount":95},[],{"trials":1322,"activeCount":95},[1323],{"nctId":1324,"briefTitle":1325,"status":292,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":196,"conditions":1329,"interventions":1330},"NCT01957059","A Phase I\u002FII Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)",[85,86],"2016-08-03","2013-06",[21],[1315,1331,1332,1333,1334],"Regimen Selection Phase Group 3","Treatment Phase Group 4","Regimen Selection Phase Group 1","Dosing Extension",{"trials":1336,"activeCount":95},[],{"trials":1338,"activeCount":95},[],{"trials":1340,"activeCount":95},[],{"intervention":1331,"totalTrials":120,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[],{"trials":1348,"activeCount":95},[1349],{"nctId":1324,"briefTitle":1325,"status":292,"phases":1350,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":196,"conditions":1351,"interventions":1352},[85,86],[21],[1315,1331,1332,1333,1334],{"trials":1354,"activeCount":95},[],{"trials":1356,"activeCount":95},[],{"trials":1358,"activeCount":95},[],{"intervention":1332,"totalTrials":120,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1362,"activeCount":95},[],{"trials":1364,"activeCount":95},[],{"trials":1366,"activeCount":95},[1367],{"nctId":1324,"briefTitle":1325,"status":292,"phases":1368,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":196,"conditions":1369,"interventions":1370},[85,86],[21],[1315,1331,1332,1333,1334],{"trials":1372,"activeCount":95},[],{"trials":1374,"activeCount":95},[],{"trials":1376,"activeCount":95},[],{"intervention":1333,"totalTrials":120,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1380,"activeCount":95},[],{"trials":1382,"activeCount":95},[],{"trials":1384,"activeCount":95},[1385],{"nctId":1324,"briefTitle":1325,"status":292,"phases":1386,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":196,"conditions":1387,"interventions":1388},[85,86],[21],[1315,1331,1332,1333,1334],{"trials":1390,"activeCount":95},[],{"trials":1392,"activeCount":95},[],{"trials":1394,"activeCount":95},[],{"intervention":1334,"totalTrials":120,"cells":1396},{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1398,"activeCount":95},[],{"trials":1400,"activeCount":95},[],{"trials":1402,"activeCount":95},[1403],{"nctId":1324,"briefTitle":1325,"status":292,"phases":1404,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":196,"conditions":1405,"interventions":1406},[85,86],[21],[1315,1331,1332,1333,1334],{"trials":1408,"activeCount":95},[],{"trials":1410,"activeCount":95},[],{"trials":1412,"activeCount":95},[],{"intervention":1414,"totalTrials":120,"cells":1415},"BMN 190 recombinant human tripeptidyl peptidase-1",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1417,"activeCount":95},[],{"trials":1419,"activeCount":95},[],{"trials":1421,"activeCount":95},[1422],{"nctId":1423,"briefTitle":1424,"status":113,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":19,"conditions":1428,"interventions":1429},"NCT02678689","A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients \u003C 18 Years of Age With CLN2 Disease",[86],"2022-04-20","2016-01-22",[1135,1136,736,1137,1138],[1414],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[],{"trials":1435,"activeCount":95},[],{"intervention":1437,"totalTrials":120,"cells":1438},"PRO044 SC",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1440,"activeCount":95},[],{"trials":1442,"activeCount":95},[],{"trials":1444,"activeCount":95},[1445],{"nctId":1446,"briefTitle":1447,"status":113,"phases":1448,"primaryCompletion":912,"completion":766,"start":1449,"enrollment":16,"conditions":1450,"interventions":1451},"NCT01037309","Phase I\u002FII Study of PRO044 in Duchenne Muscular Dystrophy (DMD)",[85,86],"2009-12",[21],[1437,1452],"PRO044 IV",{"trials":1454,"activeCount":95},[],{"trials":1456,"activeCount":95},[],{"trials":1458,"activeCount":95},[],{"intervention":1452,"totalTrials":120,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[],{"trials":1466,"activeCount":95},[1467],{"nctId":1446,"briefTitle":1447,"status":113,"phases":1468,"primaryCompletion":912,"completion":766,"start":1449,"enrollment":16,"conditions":1469,"interventions":1470},[85,86],[21],[1437,1452],{"trials":1472,"activeCount":95},[],{"trials":1474,"activeCount":95},[],{"trials":1476,"activeCount":95},[],{"intervention":1478,"totalTrials":120,"cells":1479},"6R-BH4",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1496,"PHASE4":1498,"NA":1500},{"trials":1481,"activeCount":95},[],{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[1486],{"nctId":1487,"briefTitle":1488,"status":113,"phases":1489,"primaryCompletion":1490,"completion":1491,"start":790,"enrollment":1492,"conditions":1493,"interventions":1495},"NCT00325962","A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension",[86],"2006-12","2008-12",84,[1494],"Hypertension",[1478],{"trials":1497,"activeCount":95},[],{"trials":1499,"activeCount":95},[],{"trials":1501,"activeCount":95},[],{"intervention":1503,"totalTrials":120,"cells":1504},"Phenoptin",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1506,"activeCount":95},[],{"trials":1508,"activeCount":95},[],{"trials":1510,"activeCount":95},[1511],{"nctId":1512,"briefTitle":1513,"status":113,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":127,"conditions":1517,"interventions":1520},"NCT00355264","Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency",[86],"2009-06","2006-08",[1518,1519],"Tetrahydrobiopterin Deficiencies","Hyperphenylalaninemia, Non-Phenylketonuric",[1503],{"trials":1522,"activeCount":95},[],{"trials":1524,"activeCount":95},[],{"trials":1526,"activeCount":95},[],{"intervention":1528,"totalTrials":120,"cells":1529},"Sapropterin Dihydrochloride and Vitamin C",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1531,"activeCount":95},[],{"trials":1533,"activeCount":95},[],{"trials":1535,"activeCount":95},[1536],{"nctId":1537,"briefTitle":1538,"status":113,"phases":1539,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1546},"NCT00532844","A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction",[86],"2008-11","2009-03","2007-09",52,[1545],"Endothelial Dysfunction",[1547,1528],"Sapropterin Dihydrochloride",{"trials":1549,"activeCount":95},[],{"trials":1551,"activeCount":95},[],{"trials":1553,"activeCount":95},[],{"intervention":1555,"totalTrials":120,"cells":1556},"Sapropterin",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1558,"activeCount":95},[],{"trials":1560,"activeCount":95},[],{"trials":1562,"activeCount":95},[1563],{"nctId":1564,"briefTitle":1565,"status":292,"phases":1566,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":264,"conditions":1569,"interventions":1570},"NCT01977820","Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria",[86],"2014-11","2014-02",[15],[1555],{"trials":1572,"activeCount":95},[],{"trials":1574,"activeCount":95},[],{"trials":1576,"activeCount":95},[],{"intervention":1578,"totalTrials":120,"cells":1579},"PRO045, 0.15 mg\u002Fkg\u002Fweek",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1581,"activeCount":95},[],{"trials":1583,"activeCount":95},[],{"trials":1585,"activeCount":95},[1586],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1592,"interventions":1593},"NCT01826474","Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy",[85,86],"2016-08-31","2013-01",[21],[1578,1594,1595,1596,1597,1598],"PRO045, 1.0 mg\u002Fkg\u002Fweek","PRO045, 3.0 mg\u002Fkg\u002Fweek","PRO045, 6.0 mg\u002Fkg\u002Fweek","PRO045, 9.0 mg\u002Fkg\u002Fweek","PRO045, selected dose",{"trials":1600,"activeCount":95},[],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[],{"intervention":1594,"totalTrials":120,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":95},[],{"trials":1610,"activeCount":95},[],{"trials":1612,"activeCount":95},[1613],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1614,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1615,"interventions":1616},[85,86],[21],[1578,1594,1595,1596,1597,1598],{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"intervention":1595,"totalTrials":120,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":95},[],{"trials":1628,"activeCount":95},[],{"trials":1630,"activeCount":95},[1631],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1632,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1633,"interventions":1634},[85,86],[21],[1578,1594,1595,1596,1597,1598],{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"trials":1640,"activeCount":95},[],{"intervention":1596,"totalTrials":120,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":95},[],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[1649],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1650,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1651,"interventions":1652},[85,86],[21],[1578,1594,1595,1596,1597,1598],{"trials":1654,"activeCount":95},[],{"trials":1656,"activeCount":95},[],{"trials":1658,"activeCount":95},[],{"intervention":1597,"totalTrials":120,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1662,"activeCount":95},[],{"trials":1664,"activeCount":95},[],{"trials":1666,"activeCount":95},[1667],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1668,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1669,"interventions":1670},[85,86],[21],[1578,1594,1595,1596,1597,1598],{"trials":1672,"activeCount":95},[],{"trials":1674,"activeCount":95},[],{"trials":1676,"activeCount":95},[],{"intervention":1598,"totalTrials":120,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1680,"activeCount":95},[],{"trials":1682,"activeCount":95},[],{"trials":1684,"activeCount":95},[1685],{"nctId":1587,"briefTitle":1588,"status":292,"phases":1686,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":308,"conditions":1687,"interventions":1688},[85,86],[21],[1578,1594,1595,1596,1597,1598],{"trials":1690,"activeCount":95},[],{"trials":1692,"activeCount":95},[],{"trials":1694,"activeCount":95},[],{"intervention":1696,"totalTrials":120,"cells":1697},"PRO044 SC 6 mg\u002Fkg",{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1699,"activeCount":95},[],{"trials":1701,"activeCount":95},[],{"trials":1703,"activeCount":95},[1704],{"nctId":1705,"briefTitle":1706,"status":292,"phases":1707,"primaryCompletion":1708,"completion":1590,"start":1709,"enrollment":308,"conditions":1710,"interventions":1711},"NCT02329769","Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)",[86],"2016-07-01","2014-12",[21],[1696,1712,1713],"PRO044 IV 6 mg\u002Fkg","PRO044 IV 9 mg\u002Fkg",{"trials":1715,"activeCount":95},[],{"trials":1717,"activeCount":95},[],{"trials":1719,"activeCount":95},[],{"intervention":1712,"totalTrials":120,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1732,"PHASE4":1734,"NA":1736},{"trials":1723,"activeCount":95},[],{"trials":1725,"activeCount":95},[],{"trials":1727,"activeCount":95},[1728],{"nctId":1705,"briefTitle":1706,"status":292,"phases":1729,"primaryCompletion":1708,"completion":1590,"start":1709,"enrollment":308,"conditions":1730,"interventions":1731},[86],[21],[1696,1712,1713],{"trials":1733,"activeCount":95},[],{"trials":1735,"activeCount":95},[],{"trials":1737,"activeCount":95},[],{"intervention":1713,"totalTrials":120,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1741,"activeCount":95},[],{"trials":1743,"activeCount":95},[],{"trials":1745,"activeCount":95},[1746],{"nctId":1705,"briefTitle":1706,"status":292,"phases":1747,"primaryCompletion":1708,"completion":1590,"start":1709,"enrollment":308,"conditions":1748,"interventions":1749},[86],[21],[1696,1712,1713],{"trials":1751,"activeCount":95},[],{"trials":1753,"activeCount":95},[],{"trials":1755,"activeCount":95},[],{"intervention":1757,"totalTrials":120,"cells":1758},"Moxifloxacin",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1760,"activeCount":95},[],{"trials":1762,"activeCount":95},[1763],{"nctId":1764,"briefTitle":1765,"status":113,"phases":1766,"primaryCompletion":1767,"completion":1088,"start":1768,"enrollment":756,"conditions":1769,"interventions":1770},"NCT00789568","A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects",[85],"2009-01","2008-10",[15],[1771,1757,1772],"sapropterin dihydrochloride","Moxifloxacin placebo",{"trials":1774,"activeCount":95},[],{"trials":1776,"activeCount":95},[],{"trials":1778,"activeCount":95},[],{"trials":1780,"activeCount":95},[],{"intervention":1772,"totalTrials":120,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1791,"PHASE3":1793,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":95},[],{"trials":1786,"activeCount":95},[1787],{"nctId":1764,"briefTitle":1765,"status":113,"phases":1788,"primaryCompletion":1767,"completion":1088,"start":1768,"enrollment":756,"conditions":1789,"interventions":1790},[85],[15],[1771,1757,1772],{"trials":1792,"activeCount":95},[],{"trials":1794,"activeCount":95},[],{"trials":1796,"activeCount":95},[],{"trials":1798,"activeCount":95},[],{"intervention":369,"totalTrials":120,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":95},[],{"trials":1804,"activeCount":95},[1805],{"nctId":361,"briefTitle":362,"status":113,"phases":1806,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":1807,"interventions":1808},[85],[18],[354,369],{"trials":1810,"activeCount":95},[],{"trials":1812,"activeCount":95},[],{"trials":1814,"activeCount":95},[],{"trials":1816,"activeCount":95},[],{"intervention":1818,"totalTrials":120,"cells":1819},"BMN 111 administration via Injector Pen",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1821,"activeCount":95},[],{"trials":1823,"activeCount":95},[1824],{"nctId":1825,"briefTitle":1826,"status":292,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1830,"conditions":1831,"interventions":1832},"NCT05813314","Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants",[85],"2023-06-14","2023-03-15",36,[18],[1818,1833],"BMN 111 administration via vial and syringe",{"trials":1835,"activeCount":95},[],{"trials":1837,"activeCount":95},[],{"trials":1839,"activeCount":95},[],{"trials":1841,"activeCount":95},[],{"intervention":1833,"totalTrials":120,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1845,"activeCount":95},[],{"trials":1847,"activeCount":95},[1848],{"nctId":1825,"briefTitle":1826,"status":292,"phases":1849,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1830,"conditions":1850,"interventions":1851},[85],[18],[1818,1833],{"trials":1853,"activeCount":95},[],{"trials":1855,"activeCount":95},[],{"trials":1857,"activeCount":95},[],{"trials":1859,"activeCount":95},[],{"intervention":1861,"totalTrials":120,"cells":1862},"BMN 255",{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1864,"activeCount":95},[],{"trials":1866,"activeCount":95},[1867],{"nctId":1868,"briefTitle":1869,"status":1870,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":95,"conditions":1874,"interventions":1878},"NCT06138327","A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria","WITHDRAWN",[85],"2024-03-25","2023-09-26",[1875,1876,1877],"Hyperoxaluria","Nonalcoholic Fatty Liver Disease","Kidney Stone",[1861],{"trials":1880,"activeCount":95},[],{"trials":1882,"activeCount":95},[],{"trials":1884,"activeCount":95},[],{"trials":1886,"activeCount":95},[],{"intervention":1771,"totalTrials":1888,"cells":1889},11,{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1898,"PHASE3":1930,"PHASE4":1974,"NA":1976},{"trials":1891,"activeCount":95},[],{"trials":1893,"activeCount":95},[1894],{"nctId":1764,"briefTitle":1765,"status":113,"phases":1895,"primaryCompletion":1767,"completion":1088,"start":1768,"enrollment":756,"conditions":1896,"interventions":1897},[85],[15],[1771,1757,1772],{"trials":1899,"activeCount":95},[1900,1908,1918,1926],{"nctId":1901,"briefTitle":1902,"status":113,"phases":1903,"completion":808,"start":1904,"enrollment":1905,"conditions":1906,"interventions":1907},"NCT00104260","Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria",[86],"2004-12",700,[1027],[1771],{"nctId":1909,"briefTitle":1910,"status":113,"phases":1911,"primaryCompletion":1912,"completion":1515,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1917},"NCT00445978","A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease",[86],"2008-08","2007-05",32,[1916],"Sickle Cell Disease",[1547],{"nctId":1919,"briefTitle":1920,"status":113,"phases":1921,"primaryCompletion":1540,"completion":1767,"start":1490,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT00403494","A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease",[86],190,[1924],"Intermittent Claudication",[1547],{"nctId":1537,"briefTitle":1538,"status":113,"phases":1927,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":1543,"conditions":1928,"interventions":1929},[86],[1545],[1547,1528],{"trials":1931,"activeCount":95},[1932,1940,1949,1958,1968],{"nctId":1933,"briefTitle":1934,"status":113,"phases":1935,"completion":1936,"start":1023,"enrollment":1937,"conditions":1938,"interventions":1939},"NCT00272792","Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet",[87],"2006-11",45,[1027],[1547],{"nctId":1941,"briefTitle":1942,"status":113,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT00838435","Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU",[87],"2018-09-14","2009-02",95,[15],[1771],{"nctId":1950,"briefTitle":1951,"status":113,"phases":1952,"primaryCompletion":1953,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1957},"NCT00332189","Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006",[87],"2009-08","2006-07",111,[15],[1771],{"nctId":1959,"briefTitle":1960,"status":113,"phases":1961,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1966},"NCT01114737","Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients",[87],"2013-03","2010-08",206,[15],[1967],"Sapropterin dihydrochloride",{"nctId":1969,"briefTitle":1970,"status":113,"phases":1971,"completion":818,"start":808,"enrollment":232,"conditions":1972,"interventions":1973},"NCT00225615","A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels",[87],[1027],[1771],{"trials":1975,"activeCount":95},[],{"trials":1977,"activeCount":95},[1978],{"nctId":1979,"briefTitle":1980,"status":1981,"phases":1982,"conditions":1983,"interventions":1984},"NCT00484991","Sapropterin Expanded Access Program","APPROVED_FOR_MARKETING",[],[15],[1967],{"intervention":1986,"totalTrials":29,"cells":1987},"BMN 110",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":2029,"PHASE4":2042,"NA":2044},{"trials":1989,"activeCount":95},[],{"trials":1991,"activeCount":95},[],{"trials":1993,"activeCount":95},[1994,2000,2007,2015,2022],{"nctId":1995,"briefTitle":1996,"status":113,"phases":1997,"primaryCompletion":936,"completion":1100,"start":789,"enrollment":12,"conditions":1998,"interventions":1999},"NCT00884949","A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA",[85,86],[939],[1986],{"nctId":2001,"briefTitle":2002,"status":292,"phases":2003,"primaryCompletion":753,"completion":753,"start":2004,"enrollment":12,"conditions":2005,"interventions":2006},"NCT01242111","A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",[85,86],"2010-11",[939,34,24],[1986],{"nctId":2008,"briefTitle":2009,"status":113,"phases":2010,"primaryCompletion":2011,"completion":2011,"start":2012,"enrollment":308,"conditions":2013,"interventions":2014},"NCT01515956","Study of BMN 110 in Pediatric Patients \u003C 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",[86],"2016-02","2011-10",[34,24,31],[1986],{"nctId":2016,"briefTitle":2017,"status":292,"phases":2018,"primaryCompletion":2019,"completion":2019,"start":935,"enrollment":1101,"conditions":2020,"interventions":2021},"NCT01697319","Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation",[86],"2014-10",[34,24,31],[1986],{"nctId":2023,"briefTitle":2024,"status":292,"phases":2025,"primaryCompletion":1567,"completion":1567,"start":2026,"enrollment":1090,"conditions":2027,"interventions":2028},"NCT01609062","Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",[86],"2012-04",[34,24,31],[1986,1986],{"trials":2030,"activeCount":95},[2031],{"nctId":2032,"briefTitle":2033,"status":113,"phases":2034,"primaryCompletion":2035,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2041},"NCT01966029","BMN 110 Phase 3B in Australian Patients",[87],"2016-07","2016-12","2013-07",13,[2040],"Mucopolysaccharidosis IVA (Morquio A Syndrome)",[1986],{"trials":2043,"activeCount":95},[],{"trials":2045,"activeCount":95},[2046],{"nctId":2047,"briefTitle":2048,"status":1981,"phases":2049,"conditions":2050,"interventions":2051},"NCT01858103","BMN 110 US Expanded Access Program",[],[34,24,31],[1986],{"intervention":2053,"totalTrials":162,"cells":2054},"Drisapersen",{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2069,"PHASE4":2081,"NA":2083},{"trials":2056,"activeCount":95},[],{"trials":2058,"activeCount":95},[],{"trials":2060,"activeCount":95},[2061],{"nctId":2062,"briefTitle":2063,"status":292,"phases":2064,"primaryCompletion":1266,"completion":1266,"start":2065,"enrollment":127,"conditions":2066,"interventions":2068},"NCT01910649","A Phase I\u002FII, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration",[86],"2008-03",[2067],"Muscular Dystrophies",[2053],{"trials":2070,"activeCount":95},[2071],{"nctId":2072,"briefTitle":2073,"status":292,"phases":2074,"primaryCompletion":2075,"completion":2076,"start":2077,"enrollment":2078,"conditions":2079,"interventions":2080},"NCT01803412","A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects",[87],"2016-06-01","2016-10-01","2013-05-01",53,[2067],[2053,2053,2053],{"trials":2082,"activeCount":95},[],{"trials":2084,"activeCount":95},[2085],{"nctId":2086,"briefTitle":2087,"status":2088,"phases":2089,"conditions":2090,"interventions":2091},"NCT02636686","Extension Study of Drisapersen in DMD Subjects","NO_LONGER_AVAILABLE",[],[21],[2053],{"intervention":2093,"totalTrials":264,"cells":2094},"KUVAN",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2096,"activeCount":95},[],{"trials":2098,"activeCount":95},[],{"trials":2100,"activeCount":95},[],{"trials":2102,"activeCount":95},[],{"trials":2104,"activeCount":95},[],{"trials":2106,"activeCount":95},[2107,2118],{"nctId":2108,"briefTitle":2109,"status":113,"phases":2110,"primaryCompletion":2111,"completion":2112,"start":2113,"enrollment":2114,"conditions":2115,"interventions":2117},"NCT03864029","Retrospective Observational Safety Effectiveness With Kuvan in hpA",[],"2018-03-09","2018-07-25","2017-10-10",26,[2116],"Tetrahydrobiopterin Deficiency",[2093],{"nctId":2119,"briefTitle":2120,"status":113,"phases":2121,"primaryCompletion":2122,"completion":2122,"start":2123,"enrollment":2124,"conditions":2125,"interventions":2127},"NCT00778206","PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry",[],"2021-01-29","2008-09",1887,[15,2126],"Hyperphenylalaninaemia",[2128],"Kuvan",{"intervention":2130,"totalTrials":120,"cells":2131},"Vimizim®",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[],{"trials":2137,"activeCount":95},[],{"trials":2139,"activeCount":95},[],{"trials":2141,"activeCount":95},[],{"trials":2143,"activeCount":95},[2144],{"nctId":2145,"briefTitle":2146,"status":113,"phases":2147,"primaryCompletion":2148,"completion":2148,"start":2149,"enrollment":2150,"conditions":2151,"interventions":2153},"NCT02294877","A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)",[],"2024-02-21","2014-09",418,[2152,24,31],"Mucopolysaccharidosis IV Type A",[2130],{"intervention":2155,"totalTrials":120,"cells":2156},"BMN190, recombinant human tripeptidyl peptidase-1",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2158,"activeCount":95},[],{"trials":2160,"activeCount":95},[],{"trials":2162,"activeCount":95},[],{"trials":2164,"activeCount":95},[],{"trials":2166,"activeCount":95},[],{"trials":2168,"activeCount":95},[2169],{"nctId":2170,"briefTitle":2171,"status":1981,"phases":2172,"conditions":2173,"interventions":2174},"NCT02963350","A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease",[],[1137],[2155]]